New antimicrobial strategy silences NDM-1 resistance gene in pathogens

September 8, 2014, American Society for Microbiology

Researchers have synthesized a molecule that can silence the gene responsible for severe antibiotic resistance in some bacteria. The research, presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an infectious disease meeting of the American Society for Microbiology (ASM) could be a viable new strategy for treating resistant infections.

The focus of this new molecule is NDM-1 (New Delhi metallo-beta-lactamase-1) a gene carried by some bacteria that allows them to produce an enzyme called carbapenemase.

"NDM-1 confers bacterial resistance to all classes of beta-lactam (penicillin type) antibiotics including carbapenems, powerful antibiotics used when others fail," says Bruce Geller of Oregon State University and author on the study. "NDM-1 has spread rapidly to many bacterial pathogens, including E. coli, Acinetobacter baumannii and Klebsiella pneumoniae. Many of these pathogens are resistant to multiple , which limits treatment options."

Molecule known as a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) are synthetic analogs of DNA or RNA that have the ability to silence the expression of specific genes. In this study Geller and his colleagues at Oregon State University and the University of Texas Southwestern have design, synthesized and tested a PPMO that is complimentary to the NDM-1 gene, allowing it to bind specifically to NDM-1 mRNA, essentially silencing the gene.

"When the NDM-1 PPMO was added to growing cultures of multidrug-resistant E. coli, A. baumannii or K. pneumoniae that express NDM-1, it restored susceptibility to carbapenems at therapeutically relevant concentrations," says Geller.

NDM-1 infection was first identified in 2009 in people who resided in or traveled to the India and Pakistan. The first cases in the United States were identified in 2010, and the number of cases is growing. The concern is that these highly carrying NDM-1 could supplant more antibiotic-sensitive strains.

"There is a critical need to find new treatments for antibiotic-resistant pathogens and using a gene-silencing approach, such as with a PPMO, could be one viable strategy for new antimicrobial development," says Geller.

Explore further: Team unearths what may be secret weapon against antibiotic resistance

More information: This research was presented as part of the ASM's 54th ICAAC held September 5-9, 2014 in Washington, DC.

Related Stories

Team unearths what may be secret weapon against antibiotic resistance

June 25, 2014
A fungus living in the soils of Nova Scotia could offer new hope in the pressing battle against drug-resistant germs that kill tens of thousands of people every year, including one considered a serious global threat.

Inexpensive lab test identifies resistant infections in hours

September 7, 2014
Researchers from Oregon State Public Health Lab have modified the protocol for a relatively new test for a dangerous form of antibiotic resistance, increasing its specificity to 100 percent. Their research, confirming the ...

New Delhi metallo-beta-lactamase-1 enzyme acquired in Canada

May 30, 2011
An enzyme associated with extensive antibiotic resistance called New Delhi metallo-ß-lactamase-1 (NDM-1), endemic in India and Pakistan and spreading worldwide, has been found in two people in the Toronto area, one of ...

Recommended for you

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.